Lycia Therapeutics, Inc.
Filings
| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-256/25/26 | New | $75,000,000 | $75,000,000 | Equity Only | 06b | SEC linkSEC |
| 2024-05-235/23/24 | New | $106,600,004 | $106,600,004 | Equity Only | 06b | SEC linkSEC |
| 2021-09-169/16/21 | New | $70,055,062 | $70,055,062 | Equity Only | 06b | SEC linkSEC |
| 2020-03-173/17/20 | New | $25,390,410 | $25,390,410 | Equity Only | 06b | SEC linkSEC |
Directors and Executives (Current and Past)
| Name | Role |
|---|---|
| Tim Anderson | Director |
| Amy Bachrodt | Executive |
| Jeremy S. Caldwell | Director, Executive |
| Ming Fang | Director |
| Laurent Fischer | Director |
| Andrew Gottesdiener | Director |
| Clare Ozawa | Director |
| William Rieflin | Director |
| Aetna Wun Trombley | Director, Executive |
| Thomas Woiwode | Director |
Industry: Biotechnology (See others in industry)
Address:
400 East Jamie Court, Suite 200
South San Francisco, CA, 94080
Phone: (650) 392-3357
South San Francisco, CA, 94080
Phone: (650) 392-3357